# CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

> **NCT02484391** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 48 (actual)

## Conditions studied

- Granulocytic Sarcoma
- Recurrent Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** 6,8-Bis(benzylthio)octanoic Acid
- **DRUG:** Cytarabine
- **PROCEDURE:** Hematopoietic Cell Transplantation
- **DRUG:** Mitoxantrone Hydrochloride

## Key facts

- **NCT ID:** NCT02484391
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-10
- **Final completion:** 2022-02-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484391, "CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02484391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*